Tianshuang Wu

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson et al. · JAMA Dermatology · 2021 · 485 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham et al. · JAMA Dermatology · 2020 · 216 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

Richard B. Warren, Andrew Blauvelt, Yves Poulin et al. · British Journal of Dermatology · 2020 · 206 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati et al. · Journal of the American Academy of Dermatology · 2023 · 49 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Kim Papp, Andrew Blauvelt, L. Puig et al. · Journal of the American Academy of Dermatology · 2023 · 46 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15